• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term efficacy of two sequential induction courses of Bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.

作者信息

Seo Ho Kyung, Jung Eui Hyun, Song Geehyun

机构信息

Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea.

出版信息

Transl Androl Urol. 2025 Jan 31;14(1):4-7. doi: 10.21037/tau-24-466. Epub 2025 Jan 22.

DOI:10.21037/tau-24-466
PMID:39974797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11833530/
Abstract
摘要

相似文献

1
Long-term efficacy of two sequential induction courses of Bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.卡介苗两疗程序贯诱导治疗高危非肌层浸润性膀胱癌患者的长期疗效
Transl Androl Urol. 2025 Jan 31;14(1):4-7. doi: 10.21037/tau-24-466. Epub 2025 Jan 22.
2
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求：国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.
3
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.卡介苗联合α干扰素膀胱灌注与单纯卡介苗膀胱灌注治疗非肌层浸润性膀胱癌的比较
Cochrane Database Syst Rev. 2017 Mar 8;3(3):CD012112. doi: 10.1002/14651858.CD012112.pub2.
4
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.CREST 研究：sasanlimab 联合卡介苗治疗卡介苗初治高危非肌层浸润性膀胱癌患者的 III 期临床研究。
Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8.
5
Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.高危非肌层浸润性膀胱癌患者接受卡介苗治疗的 2 个诱导疗程的反应：2 期临床试验的 5 年随访。
JAMA Oncol. 2024 Apr 1;10(4):522-525. doi: 10.1001/jamaoncol.2023.6804.
6
Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer.在高级别非肌层浸润性膀胱癌患者中，人工智能驱动的预测生物标志物的存在与对膀胱内卡介苗治疗反应不佳相关，但与膀胱内序贯吉西他滨/多西他赛治疗反应不佳无关。
Eur Urol Oncol. 2025 Apr 25. doi: 10.1016/j.euo.2025.04.006.
7
Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.上尿路尿路上皮癌对非肌肉浸润性膀胱癌患者对卡介苗反应的影响。
BJU Int. 2021 Nov;128(5):568-574. doi: 10.1111/bju.15344. Epub 2021 Feb 15.
8
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.使用复发性肿瘤分级来指导卡介苗治疗：低级别复发并非良性。
Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.
9
Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis.膀胱内化疗与卡介苗联合治疗对比卡介苗单药治疗中高危非肌层浸润性膀胱癌：一项系统评价与Meta分析
Medicine (Baltimore). 2016 Jan;95(3):e2572. doi: 10.1097/MD.0000000000002572.
10
A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Guérin Instillation for Non-muscle-invasive Bladder Cancer.预防性喹诺酮类药物联合卡介苗灌注对非肌层浸润性膀胱癌临床影响的系统评价和荟萃分析
Eur Urol Oncol. 2025 Apr;8(2):571-580. doi: 10.1016/j.euo.2024.12.013. Epub 2025 Jan 28.

本文引用的文献

1
Theories behind Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer and update on current management.高危非肌层浸润性膀胱癌中卡介苗治疗失败的理论及当前治疗进展
Cancer Pathog Ther. 2023 Nov 29;2(2):74-80. doi: 10.1016/j.cpt.2023.11.004. eCollection 2024 Apr.
2
Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.高危非肌层浸润性膀胱癌患者接受卡介苗治疗的 2 个诱导疗程的反应：2 期临床试验的 5 年随访。
JAMA Oncol. 2024 Apr 1;10(4):522-525. doi: 10.1001/jamaoncol.2023.6804.
3
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
4
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.atezolizumab 在卡介苗无应答高危非肌肉浸润性膀胱癌中的 2 期临床试验：SWOG S1605。
Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.
5
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.不同卡介苗（BCG）菌株对中/高危非肌层浸润性膀胱癌（NMIBC）复发率的疗效：单臂研究的系统评价、累积和网状荟萃分析
Cancers (Basel). 2023 Mar 23;15(7):1937. doi: 10.3390/cancers15071937.
6
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.高风险或极高风险非肌层浸润性膀胱癌患者行 8 剂卡介苗非维持膀胱内诱导治疗：一项回顾性非随机对照研究。
BMC Cancer. 2021 Mar 11;21(1):266. doi: 10.1186/s12885-021-07966-7.
7
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.纳武拉非尼基因导管治疗卡介苗无应答性非肌肉浸润性膀胱癌：一项单臂、开放标签、重复剂量临床试验。
Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.
8
Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.训练免疫作为膀胱癌卡介苗免疫治疗的分子机制。
Nat Rev Urol. 2020 Sep;17(9):513-525. doi: 10.1038/s41585-020-0346-4. Epub 2020 Jul 16.
9
Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".标准剂量和次数的卡介苗灌注与减少剂量和次数的卡介苗灌注治疗高级别非肌肉浸润性膀胱癌：欧洲泌尿外科学会研究基金会随机 III 期临床试验“NIMBUS”的结果。
Eur Urol. 2020 Nov;78(5):690-698. doi: 10.1016/j.eururo.2020.04.066. Epub 2020 May 20.
10
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.KEYNOTE-676：卡介苗和帕博利珠单抗用于持续性/复发性高危非肌层浸润性膀胱癌的 III 期研究。
Future Oncol. 2020 Apr;16(10):507-516. doi: 10.2217/fon-2019-0817. Epub 2020 Mar 12.